Exploring construct validity of clinical staging in schizophrenia spectrum disorders in an acute psychiatric ward

Berendsen, Steven; Paardt, Jasper van der; Bruggen, Marion van; Nusselder, Hans; Jalink, Margje; Peen, Jaap; Van, Henricus L.; Dekker, Jack; Haan, Lieuwe de

doi:10.3371/csrp.bepa.061518

Cited by 8 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier reports regarding variation in symptom severity between clinical stages provided variable results. Two studies reported higher index severity scores of negative symptoms and cognitive decline in stage 4 compared to earlier stages (Berendsen et al, 2018;Godin et al, 2019). On the other hand, Tedja and colleagues found that baseline stages were not associated with negative symptoms at follow-up and cognition was primarily not affected (Tedja et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, clinical staging of schizophrenia spectrum disorders has received increased attention in scientific literature. Three exploratory validation studies of the staging model in schizophrenia demonstrated that more advanced stages of disease have higher severity scores at symptom level and a wide variety of clinical profilers (Berendsen et al, 2018;Godin et al, 2019;Tedja, Velthorst, van Tricht, de Haan, & Group, 2017). More specifically, two of these studies suggested that advanced disease stages have higher severity scores of depression, cognitive decline and negative symptoms.…”

Section: Introductionmentioning

confidence: 99%

“…In more detail, a prolonged DUP of at least 9 months to 1 year is associated with significantly more severe negative and positive symptoms at baseline and shortterm (<2 years) follow-up (Boonstra et al, 2012;Marshall et al, 2005;Perkins, Gu, Boteva, & Lieberman, 2005). For this reason, an earlier study suggested to split stage 2 (FEP) dependent on the DUP, since the authors noticed that patients with a long DUP presented with a worse psychiatric condition in terms of symptom severity and therapy-resistance (Berendsen et al, 2018). To the best of our knowledge no former study investigated the validity of splitting stage 2 dependent on the DUP.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders

Berendsen

Van

Paardt

et al. 2020

Early Intervention Psych

Self Cite

View full text Add to dashboard Cite

Aim: Clinical staging of schizophrenia entails a new method that identifies clusters of symptoms and variation in level of remission, with the goal to create a framework for early intervention. Additionally, duration of untreated psychosis (DUP) may influence symptom severity in the first episode of psychosis (FEP) and could necessitate refining of the staging model. However, consistent evidence concerning variation in symptom severity and DUP between stages is missing. Therefore, we evaluated the clinical validity of the staging model by investigating differences in symptom severity across stages in schizophrenia spectrum disorders. Second, we assessed if a prolonged DUP is associated with higher symptom severity in FEP. Methods: We performed a cross-sectional study of 291 acutely admitted patients with a schizophrenia spectrum disorder. Patients were assigned to clinical stages following the definition of McGorry. Symptom severity was evaluated with the new DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS). In FEP, we determined the DUP. Results: Significantly higher severity scores of CRDPSS items hallucinations

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders

Berendsen

Van

Paardt

et al. 2020

Early Intervention Psych

Self Cite

View full text Add to dashboard Cite

show abstract

“…Future studies should take into account the fact that schizophrenia is diagnosed based on a sum of different clinical criteria, and this could lead to different types of schizophrenia with different biomarkers. Moreover, in schizophrenia different clinical stages have been described 42,43 that could be based in different neurobiological alterations, and this could affect the retinal parameters. Finally, regarding this disease, some studies suggest that it is a neurodevelopment illness 44,45 while others support a neurodegenerative component (Gupta et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Usefulness of Optical Coherence Tomography Measures as Biomarkers in Schizophrenia

Rodríguez‐Jiménez¹

2018

J Neurol Neuromed

View full text Add to dashboard Cite

Optical coherence tomography (OCT) is a non-invasive imaging technique recently used to investigate neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease or multiple sclerosis. Over the last years it has been used in schizophrenia research due to the potential utility of its measurements as biomarkers of the disease. From the first publication by Ascaso et al. (Eur J Psychiat. 2010) until now, a number of papers have been published regarding this topic. Although the majority of them have found a reduction in the thickness or the volume of some retinal and optic nerve structures, there have also been some results with contradictory data. These could be due on the one hand to methodological factors such as the use of different OCT devices or the inclusion/ exclusion criteria. On the other hand, there could be an important limitation due to the fact that the different stages of the disorder and their different neurobiological correlates and biomarkers were not taken into consideration. Future longitudinal studies, that begin the assessments in the first psychotic episode (or even before, in ultra-high risk population) are needed in order to clarify the potential role of some OCT measures as biomarkers in schizophrenia.

show abstract

“…In this regard, the recently developed models based solely on the Positive and Negative Syndrome Scale (PANSS) deserve a separate mention [11][12][13]. Additionally, we have noticed a growing interest in validating some of the proposed theoretical models [6] for the purpose of establishing their validity and/or improving them [14][15][16][17][18][19][20][21][22]. However, despite these above-mentioned efforts, practically all of these models have significant limitations [6].…”

Section: Introductionmentioning

confidence: 99%

PsiOvi Staging Model for Schizophrenia (PsiOvi SMS): A New Internet Tool for Staging Patients with Schizophrenia

Martínez-Cao,

Sánchez-Lasheras,

García-Fernández

et al. 2024

Eur. Psychiatr.

View full text Add to dashboard Cite

Background. One of the challenges of psychiatry is the staging of patients, especially those with severe mental disorders. Therefore, we aim to develop an empirical staging model for schizophrenia. Methods. Data were obtained from 212 stable outpatients with schizophrenia: demographic, clinical, psychometric (PANSS, CAINS, CDSS, OSQ, CGI-S, PSP, MATRICS), inflammatory peripheral blood markers (C-reactive protein, interleukins-1RA and 6, and platelet/lymphocyte [PLR], neutrophil/lymphocyte [NLR], and monocyte/lymphocyte [MLR] ratios). We used machine learning techniques to develop the model (genetic algorithms, support vector machines) and applied a fitness function to measure the model's accuracy (% agreement between patient classification of our model and the CGI-S). Results. Our model includes 12 variables from 5 dimensions: 1) psychopathology: positive, negative, depressive, general psychopathology symptoms; 2) clinical features: number of hospitalizations; 3) cognition: processing speed, visual learning, social cognition; 4) biomarkers: PLR, NLR, MLR; and 5) functioning: PSP total score. Accuracy was 62% (SD = 5.3), and sensitivity values were appropriate for mild, moderate, and marked severity (from 0.62106 to 0.6728). Discussion. We present a multidimensional, accessible, and easy-to-apply model that goes beyond simply categorizing patients according to CGI-S score. It provides clinicians with a multifaceted patient profile that facilitates the design of personalized intervention plans.

show abstract

Exploring construct validity of clinical staging in schizophrenia spectrum disorders in an acute psychiatric ward

Cited by 8 publications

References 1 publication

Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders

Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders

Usefulness of Optical Coherence Tomography Measures as Biomarkers in Schizophrenia

PsiOvi Staging Model for Schizophrenia (PsiOvi SMS): A New Internet Tool for Staging Patients with Schizophrenia

Contact Info

Product

Resources

About